Amrize (AMRZ) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
19 analysts covering Amrize (AMRZ) carry an average price target of $45.28 as of November 2026, +4.9% against the $43.18 price at the time of the pull. The published targets run from $32.00 to $55.00, a spread of 51% of the average, so the disagreement is moderate. The rating split is 9 buy, 9 hold, 2 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.
AMRZ analyst price targets
AMRZ analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.
The average target of $45.28 sits roughly in line with the $43.18 price, +4.9%. The median is $45.50, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.
What the AMRZ target range actually tells you
The published targets span $32.00 to $55.00. That gap is 51% of the average target, which counts as moderate disagreement. A spread like this is fairly typical: enough agreement that the average means something, enough disagreement that it should not be treated as precise.
The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the AMRZ is it a buy page.
Recent analyst actions on AMRZ
| Firm | Action | Target | Prior | Date |
|---|---|---|---|---|
| Oppenheimer | Lowered (Outperform) | $52.00 | $55.00 | November 2, 2026 |
| DA Davidson | Raised (Neutral) | $43.00 | $40.00 | October 30, 2026 |
| Wells Fargo | Lowered (Equal-Weight) | $39.00 | $40.00 | October 30, 2026 |
| Barclays | Lowered (Equal-Weight) | $40.00 | $55.00 | October 19, 2026 |
| JP Morgan | Lowered (Neutral) | $48.00 | $52.00 | October 13, 2026 |
| Longbow Research | Initiated (Buy) | - | - | October 12, 2026 |
| RBC Capital | Lowered (Underperform) | $32.00 | $48.00 | October 9, 2026 |
| Wells Fargo | Lowered (Equal-Weight) | $40.00 | $44.00 | October 5, 2026 |
| Truist Securities | Lowered (Hold) | $35.00 | $48.00 | October 5, 2026 |
| Citigroup | Lowered (Buy) | $50.00 | $58.00 | October 2, 2026 |
| Barclays | Initiated (Equal-Weight) | $55.00 | - | October 1, 2026 |
| Deutsche Bank | Lowered (Buy) | $56.00 | $64.00 | September 23, 2026 |
The most recent published rating actions on AMRZ within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.
In the last six months there has been 1 raise and 9 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.
How analysts rate AMRZ
Of the analysts with a published rating, 9 say buy, 9 say hold, and 2 say sell, so 45% carry a buy. That buy share has fallen over the last three months, so sentiment is drifting more negative.
The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.
Why a AMRZ price target is not a prediction
- It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
- The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
- Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
- Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.
AMRZ earnings and revenue forecast
For the fiscal year ending Dec 2026, the 17 analysts publishing estimates on AMRZ expect earnings of $2.29 per share (+7.2% on the year before) and revenue of $12.3 billion (+4.5%).
| Period | EPS estimate | EPS growth | Revenue estimate | Revenue growth |
|---|---|---|---|---|
Quarter ending Dec 2026 next quarter to report, 7 analysts | $0.57 $0.52 to $0.60 | +5.5% | $2.9 billion | +2.2% |
Quarter ending Mar 2027 the quarter after, 6 analysts | -$0.20 -$0.27 to -$0.12 | n/a | $2.2 billion $2 billion to $2.3 billion | +2.7% |
Fiscal year ending Dec 2026 fiscal year next to report, 17 analysts | $2.29 $2.20 to $2.41 | +7.2% | $12.3 billion $12.3 billion to $12.4 billion | +4.5% |
Fiscal year ending Dec 2027 the fiscal year after, 22 analysts | $2.60 $2.15 to $2.91 | +13% | $13.1 billion $11.8 billion to $13.7 billion | +5.7% |
Consensus estimates for AMRZ published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.
Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Amrize next reports on October 28, 2026, which is when these figures get tested against actual results.
Is there a 2030 forecast for AMRZ?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering AMRZ do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $2.60 per share, +13% on the fiscal year ending Dec 2026 estimate of $2.29. Beyond that, nobody publishes estimates, so any later number is an extrapolation.
On the figures we hold as of November 2026, AMRZ trades at about 19.4 times trailing earnings and 16.3 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Amrize can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move AMRZ from here
In short: the drivers cited most often are Mega-project demand for cement and aggregates, Pricing catching up to oil-linked costs, Bolt-on M&A in a fragmented aggregates market. The risk cited most often against it is construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the AMRZ is it a buy page.
Investing in Amrize with AI
Connect the broker you already use and ask Walnut's AI how AMRZ fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Amrize (AMRZ)?
+
The average analyst price target for AMRZ is $45.28 as of November 2026, across 19 analysts. The average is +4.9% against the $43.18 price at the time of the data pull, so the consensus sits roughly in line with where the stock trades. The median target, which is less distorted by one extreme view, is $45.50. Targets move constantly; verify the current figure before relying on it.
How high could AMRZ go?
+
The highest published target is $55.00, which is +27.4% against the $43.18 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $32.00. The gap between them answers this question best: analysts who all follow Amrize closely disagree by 51% of the average target, so treat any single number as one scenario.
How many analysts cover AMRZ?
+
19 analysts publish estimates on AMRZ as of November 2026. Of those with a published rating, 9 say buy, 9 hold, and 2 sell, so 45% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.
Are analyst price targets for AMRZ accurate?
+
Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and AMRZ is no exception at 45% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.
Has the AMRZ price target been raised or cut recently?
+
In the last six months there has been 1 raise and 9 cuts among the published actions on AMRZ. The most recent was Oppenheimer, which lowered its target to $52.00 from $55.00 on November 2, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.
Is analyst sentiment on AMRZ improving?
+
Over the last three months the share of analysts rating AMRZ a buy has been falling. The shift is in opinion, not in the business, and it often lags the news that caused it. It is best read alongside the target revisions.
What are analysts' earnings estimates for Amrize (AMRZ)?
+
For the fiscal year ending Dec 2026, the 17 analysts publishing estimates on AMRZ expect earnings of $2.29 per share (+7.2% on the year before) and revenue of $12.3 billion (+4.5%). For the fiscal year ending Dec 2027, the consensus is $2.60 per share, +13% on the year before. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.
When does AMRZ report earnings next?
+
Amrize's next earnings report is scheduled for October 28, 2026. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.
What is the AMRZ stock price prediction for 2030?
+
There is no published one. Analyst targets run to about twelve months and no firm covering AMRZ publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Amrize's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.
Will AMRZ go up in 2026?
+
Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Amrize: Construction materials is a cyclical, interest-rate-sensitive business, and residential roofing and ready-mix demand can turn faster than cement plants can flex output. Walnut is not an investment adviser.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.